Radionuclide imaging uses a special detector (gamma camera) to create an image following injection of radioactive material. This test is done to evaluate.
Radionuclide imaging exposes patients to less radiation than do comparable x-ray studies. However, because the radioactive material is retained in the patient briefly, sophisticated radiation alarms (eg, in airports) may be triggered by the patient for several days after such testing
Planar techniques, which produce a 2-dimensional image, are rarely used; SPECT, which uses a rotating camera system and tomographic reconstruction to produce a 3-dimensional image, is more common in the US. With multihead SPECT systems, imaging can often be completed in ≤ 10 min. Visual comparison of stress and delayed images can be supplemented by quantitative displays. With SPECT, the following can be identified:
The mass of infarcted and viable myocardium can be quantified, helping determine prognosis.
In myocardial perfusion imaging, IV radionuclides are taken up by cardiac tissues in rough proportion to perfusion; thus, areas of decreased uptake represent areas of relative or absolute ischemia.
Attenuation of myocardial activity by overlying soft tissue may cause false-positive results. Attenuation by breast tissue in women is especially common. Attenuation by the diaphragm and abdominal contents may produce spurious inferior wall defects in both sexes but is more common among men. Attenuation is more likely with technetium-99m (99mTc) than with radioactive thallium-201 (201Tl).
Myocardial perfusion imaging is used with stress testing to
Evaluate patients with chest pain of uncertain origin
Determine the functional significance of coronary artery stenosis seen on angiography
Determine the functional significance of collateral vessels seen on angiography
Evaluate the success of reperfusion interventions (eg, coronary artery bypass grafting [CABG], percutaneous intervention, thrombolysis)
Estimate prognosis after myocardial infarction
After acute myocardial infarction, myocardial perfusion imaging can help estimate prognosis because it can show extent of the perfusion abnormality due to acute myocardial infarction, extent of scarring due to previous infarcts, and residual peri-infarct or other areas of reversible ischemia.
Various protocols are used depending on the imaging agent, which include
Radioactive thallium-201 (201Tl), which acts as a potassium analog, was the original tracer used in stress testing. It is injected at peak stress and imaged with SPECT, followed 4 h later by injection of half the original dose during rest and by repeat SPECT. The goal of this protocol is to evaluate reversible perfusion defects that may warrant intervention. After stress testing, the perfusion imbalance between normal coronary arteries and those distal to a stenosis appears as a relative decrease in 201Tl uptake in the areas perfused by the stenosed arteries. Sensitivity of stress testing with 201Tl for CAD is similar whether imaging is done after exercise stress or pharmacologic stress.
Several technetium-99m (99mTc) myocardial perfusion markers have been developed because the imaging characteristics of 201Tl are not ideal for the gamma camera. Markers include sestamibi (commonly used), tetrofosmin, and teboroxime (see Table: Technetium-99m (99mTc) Myocardial Perfusion Markers). Protocols include 2-day stress-rest, 1-day rest-stress, and 1-day stress-rest. Some protocols use dual isotopes (201Tl and 99mTc), although this approach is expensive. With either of these markers, sensitivity is about 90%, and specificity is about 71%.
For 2-day protocols, imaging at rest may be omitted if the initial stress test shows no evidence of abnormal perfusion. When higher doses of 99mTc (> 30 mCi) are used, first-transit function studies (with ventriculography) may be used with perfusion imaging.
Other radionuclides include iodine-123 (123I)–labeled fatty acids, which produces cold spots where myocardium is ischemic; gallium citrate-67 (67Ga), which accumulates in sites of active inflammation (eg, in acute inflammatory cardiomyopathy); and 123I metaiodobenzylguanidine, a neurotransmitter analog taken up and stored in neurons of the sympathetic nervous system and used in research to evaluate heart failure, diabetes, pheochromocytoma, certain arrhythmias, and arrhythmogenic right ventricular dysplasia.
Technetium-99m (99mTc) Myocardial Perfusion Markers
Infarct avid imaging uses radiolabeled markers that accumulate in areas of damaged myocardium, such as 99mTc pyrophosphate and antimyosin (indium-111 [111In]–labeled antibodies to cardiac myosin). Images usually become positive 12 to 24 h after acute myocardial infarction and remain positive for about 1 wk; they may remain positive if myocardial necrosis continues post-MI or if aneurysms develop. This technique is rarely used now because other diagnostic tests for myocardial infarction (eg, biomarkers) are more readily available and less expensive and because it provides no prognostic information other than infarct size.
Radionuclide ventriculography is used to evaluate ventricular function. It is useful for measuring resting and exercise ejection fraction in coronary artery disease, valvular heart disease, and congenital heart disease. Some clinicians prefer it for serial assessment of ventricular function in patients taking cardiotoxic cancer chemotherapy (eg, anthracyclines). However, radionuclide ventriculography has been largely replaced by echocardiography, which is less expensive, does not require radiation exposure, and theoretically can measure ejection fractions as accurately.
99mTc-labeled RBCs are injected intravenously. Left ventricular (LV) and right ventricular (RV) function can be evaluated by or by
Either study can be done during rest or after exercise. First-transit studies are rapid and relatively easy, but MUGA provides better images and is more widely used.
In first-transit studies, 8 to 10 cardiac cycles are imaged as the marker mixes with blood and passes through the central circulation. First-transit studies are ideal for assessing RV function and intracardiac shunts.
In MUGA, imaging is synchronized with the R wave of the ECG. Multiple images are taken of short, sequential portions of each cardiac cycle for 5 to 10 min. Computer analysis generates an average blood pool configuration for each portion of the cardiac cycle and synthesizes the configurations into a continuous cinematic loop resembling a beating heart.
MUGA can quantitate numerous indexes of ventricular function, including regional wall motion, ejection fraction (EF); ratio of stroke volume to end-diastolic volume, ejection and filling rates, LV volume, and indexes of relative volume overload (eg, LV:RV stroke volume ratios). EF is used most commonly.
MUGA during rest has virtually no risk. It is used for serially evaluating RV and LV function in various disorders (eg, valvular heart disorders); for monitoring patients taking potentially cardiotoxic drugs (eg, doxorubicin); and for assessing the effects of angioplasty, CABG, thrombolysis, and other procedures in patients with CAD or MI. Arrhythmias are a relative contraindication because there may be few normal cardiac cycles.
MUGA is useful for detecting left ventricular aneurysms; sensitivity and specificity are > 90% for typical anterior or anteroapical true aneurysms. Conventional gated blood pool imaging shows inferoposterior LV aneurysms less well than it shows anterior and lateral aneurysms; additional views are required. Gated SPECT imaging takes longer (about 20 to 25 min with a multihead camera) than a single planar gated view (5 to 10 min) but shows all portions of the ventricles.
MUGA is used to assess right ventricular function in patients who have a lung disorder or an inferior left ventricular infarct that may involve the RV. Normally, right ventricular ejection fraction (40 to 55% with most techniques) is lower than left ventricular ejection fraction. RVEF is subnormal in many patients with pulmonary hypertension and in patients with RV infarction or cardiomyopathy affecting the RV. Idiopathic cardiomyopathy is usually characterized by biventricular dysfunction, unlike typical coronary artery disease, which usually causes more left ventricular than right ventricular dysfunction.
MUGA can be used with rest-stress protocols to assess valvular disorders that result in left ventricular volume overload. In aortic regurgitation, a reduction in resting EF or no increase in EF with exercise is a sign of deteriorating cardiac function and may indicate a need for valvular repair. MUGA also can be used to calculate the regurgitant fraction in regurgitation of any valve. Normally, the stroke volume of the 2 ventricles is equal. However, in patients with left-sided valvular regurgitation, LV stroke volume exceeds that of the right ventricle by an amount proportional to the regurgitant fraction. Thus, if the RV is normal, the regurgitant fraction of the LV can be calculated from the LV:RV stroke volume ratio.